Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.11/Share
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.69 -0.37%
Revenue Growth %: -33.6%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES: -6.35M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -33.6%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES: -6.35M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.11), versus ($0.05) reported last year. Revenue for the quarter came in at $1.77 million, versus $1.34 million reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold
- DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
